Pharma Pulse 9/24/24: Wall Street Skeptic Rings AI Alarm, A Different Approach to Dermatology Care & more

A Different Approach to Dermatology Care

Brian Hillberdink, EVP, LEO Pharma and President of LEO Pharma's US affiliate, discusses their approach to orphan drug development, challenges and opportunities adapting to the US market, and more.

RSV Vaccine Keeps Older People Out of the Hospital

Results looking at the first season of RSV use shows that it is 75% effective at preventing RSV-associated hospitalizations in those 60 and older.

Will A.I. Be a Bust? A Wall Street Skeptic Rings the Alarm.

Jim Covello, Goldman Sachs’s head of stock research, warned that building too much of what the world doesn’t need “typically ends badly.”

Kenvue Drives Climate Action Strategy Forward

Kenvue Inc., the maker of iconic brands such as Aveeno®, Listerine®, Neutrogena® and Tylenol®, is advancing progress toward the climate change goals outlined in its Healthy Lives Mission environmental, social and governance strategy, including releasing its first Task Force on Climate-related Financial Disclosures (TCFD) report.

Nicholas Saraceno on LinkedIn

#LogiPharmaUS is upon us! On behalf of Pharmaceutical Commerce Magazine, it’s great to be back in Boston alongside Donald Tracy, MA and Brian Haug (not pictured), who is already out and about making deals. Always invigorating to be surrounded by the best of the best pharmaeutical supply chain innovators. Stay tuned for upcoming session coverage and behind-the-scenes video interviews. LogiPharma US

Have news you want us to share in Pharma Pulse? Reach out to Social Media Editor Miranda Schmalfuhs